[go: up one dir, main page]

MX2009008046A - Nuevo procedimiento de obtencion de la forma cristalina y de la agomelatina. - Google Patents

Nuevo procedimiento de obtencion de la forma cristalina y de la agomelatina.

Info

Publication number
MX2009008046A
MX2009008046A MX2009008046A MX2009008046A MX2009008046A MX 2009008046 A MX2009008046 A MX 2009008046A MX 2009008046 A MX2009008046 A MX 2009008046A MX 2009008046 A MX2009008046 A MX 2009008046A MX 2009008046 A MX2009008046 A MX 2009008046A
Authority
MX
Mexico
Prior art keywords
agomelatine
gen
crystalline form
obtaining
new process
Prior art date
Application number
MX2009008046A
Other languages
English (en)
Inventor
Pascal Langlois
Gerard Coquerel
Julie Linol
Damien Martins
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40418877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009008046(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2009008046A publication Critical patent/MX2009008046A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)

Abstract

Procedimiento de obtención de la forma cristalina V del compuesto de fórmula (I): (ver fórmula I).
MX2009008046A 2008-08-05 2009-07-29 Nuevo procedimiento de obtencion de la forma cristalina y de la agomelatina. MX2009008046A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0804466A FR2934856B1 (fr) 2008-08-05 2008-08-05 Nouveau procede d'obtention de la forme cristalline v de l'agomelatine

Publications (1)

Publication Number Publication Date
MX2009008046A true MX2009008046A (es) 2010-03-23

Family

ID=40418877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008046A MX2009008046A (es) 2008-08-05 2009-07-29 Nuevo procedimiento de obtencion de la forma cristalina y de la agomelatina.

Country Status (45)

Country Link
US (1) US8252957B2 (es)
EP (1) EP2151430B1 (es)
JP (1) JP5047240B2 (es)
KR (1) KR101118335B1 (es)
CN (1) CN101643432B (es)
AP (1) AP3196A (es)
AR (1) AR074889A1 (es)
AT (1) ATE518825T1 (es)
AU (1) AU2009203071B2 (es)
BR (1) BRPI0903058A2 (es)
CA (1) CA2674770C (es)
CL (1) CL2009001685A1 (es)
CO (1) CO6120151A1 (es)
CR (1) CR10952A (es)
CY (1) CY1111873T1 (es)
DK (1) DK2151430T3 (es)
EA (1) EA016896B1 (es)
EC (1) ECSP099554A (es)
ES (1) ES2371047T3 (es)
FR (1) FR2934856B1 (es)
GE (1) GEP20125408B (es)
GT (1) GT200900215A (es)
HN (1) HN2009001437A (es)
HR (1) HRP20110712T1 (es)
IL (1) IL200126A (es)
JO (1) JO2812B1 (es)
MA (1) MA31223B1 (es)
ME (1) ME00929B (es)
MX (1) MX2009008046A (es)
MY (1) MY151042A (es)
NI (1) NI200900154A (es)
NZ (1) NZ578826A (es)
PE (1) PE20100153A1 (es)
PL (1) PL2151430T3 (es)
PT (1) PT2151430E (es)
RS (1) RS52002B (es)
SA (1) SA109300499B1 (es)
SG (1) SG158830A1 (es)
SI (1) SI2151430T1 (es)
SV (1) SV2009003345A (es)
TW (1) TW201008901A (es)
UA (1) UA102816C2 (es)
UY (1) UY32014A (es)
WO (1) WO2010015747A1 (es)
ZA (1) ZA200905334B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101781226B (zh) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
EP2705023A4 (en) * 2011-01-04 2014-11-19 Symed Labs Ltd PROCESSES FOR THE PREPARATION OF N- [2- (7-METHOXY-1-NAPHTHYLLELYHYL) ACETAMIDE
WO2012130837A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Solid agomelatine in non-crystalline form
EP2872129B1 (en) 2012-07-16 2017-03-08 ratiopharm GmbH Complex of agomelatine and cyclodextrin
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1703641A1 (ru) * 1988-02-23 1992-01-07 Ростовский государственный университет Способ получени 3,5-ди-трет.бутил-4-оксиацетанилида
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
WO2008141033A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals Inc. Substituted naphthalenes
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
CN101643432B (zh) 2012-12-12
EA016896B1 (ru) 2012-08-30
CR10952A (es) 2009-10-15
ATE518825T1 (de) 2011-08-15
FR2934856B1 (fr) 2010-08-13
PT2151430E (pt) 2011-08-25
CY1111873T1 (el) 2015-11-04
US20100036165A1 (en) 2010-02-11
JP2010037345A (ja) 2010-02-18
SA109300499B1 (ar) 2013-10-06
ZA200905334B (en) 2010-05-26
IL200126A0 (en) 2010-05-31
AP3196A (en) 2015-03-31
WO2010015747A1 (fr) 2010-02-11
HN2009001437A (es) 2011-09-22
RS52002B (sr) 2012-04-30
SG158830A1 (en) 2010-02-26
EP2151430A1 (fr) 2010-02-10
UA102816C2 (ru) 2013-08-27
MY151042A (en) 2014-03-31
SI2151430T1 (sl) 2011-10-28
KR20100017070A (ko) 2010-02-16
FR2934856A1 (fr) 2010-02-12
NI200900154A (es) 2010-03-25
PL2151430T3 (pl) 2011-12-30
HK1141005A1 (en) 2010-10-29
KR101118335B1 (ko) 2012-03-09
JO2812B1 (en) 2014-09-15
GEP20125408B (en) 2012-02-27
IL200126A (en) 2013-04-30
GT200900215A (es) 2011-07-19
EP2151430B1 (fr) 2011-08-03
CO6120151A1 (es) 2010-01-29
ECSP099554A (es) 2010-03-31
MA31223B1 (fr) 2010-03-01
CL2009001685A1 (es) 2010-07-19
TW201008901A (en) 2010-03-01
BRPI0903058A2 (pt) 2010-05-25
HRP20110712T1 (hr) 2011-11-30
SV2009003345A (es) 2010-02-01
CA2674770C (fr) 2012-04-17
DK2151430T3 (da) 2011-11-21
UY32014A (es) 2010-01-29
US8252957B2 (en) 2012-08-28
JP5047240B2 (ja) 2012-10-10
AU2009203071B2 (en) 2013-10-31
AU2009203071A1 (en) 2010-02-25
EA200900944A1 (ru) 2010-04-30
ES2371047T3 (es) 2011-12-26
NZ578826A (en) 2010-11-26
CA2674770A1 (fr) 2010-02-05
ME00929B (me) 2012-06-20
AR074889A1 (es) 2011-02-23
AP2009004936A0 (en) 2009-08-31
PE20100153A1 (es) 2010-03-06
CN101643432A (zh) 2010-02-10

Similar Documents

Publication Publication Date Title
MX2009008046A (es) Nuevo procedimiento de obtencion de la forma cristalina y de la agomelatina.
NI201100026A (es) Nuevos derivados de sulfamida sustituidos
MX2009008047A (es) Nuevo procedimiento de sintesis de la agomelatina.
JP2012092127A5 (es)
MY159816A (en) New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
CY1119474T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
UY31934A (es) Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
FI4293009T3 (fi) Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi
PE20070365A1 (es) Forma cristalina de n-[2-(7-metoxi-1-naftil)etil]acetamida (agomelatina), su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
DK1656122T3 (da) Transdermale lægemiddeltilberedninger med kombinationer af aktive stoffer til behandling af Parkinsons syge
BR112012010859A2 (pt) ''composto,formulação farmacêutica,processo de preparação de um composto,uso de um composto e método de tratamento ou profilaxia de distúrbio proliferativos celulares''
SG171681A1 (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
MX342807B (es) Cocristales farmacéuticamente aceptables de n- [2-(7-metoxi-1-naftil) etil] acetamida y métodos para su preparación.
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
UY26290A1 (es) Compuestos químicos xxi
PE20080174A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del trastorno de la ansiedad generalizada
WO2010014613A3 (en) Treating various disorders using trkb agonists
GR1007686B (el) Συνθεση των (+) και (-) 1-(5,5-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης, (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης και (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν-μεθυλομεθυλαμινης
Zhu et al. Transfer hydrogenation of imines with carboxyl-tailed benzothiazoline as readily removable hydrogen donor
BRPI0919635A8 (pt) Processo para preparação de cinacalcet
Paquette et al. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism
MY148880A (en) N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
UA107201C2 (uk) 4-[етил(диметил)амоній]бутаноат та його застосування в лікуванні серцево-судинної хвороби
BRPI0514579A (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e gaboxadol, e, processo para preparo de um composto
SG195309A1 (en) Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Legal Events

Date Code Title Description
FG Grant or registration